Browsing by Author "Milović-Kovačević, Marijana (15136517400)"

Introduction Ribociclib belongs to the family of cyclin-dependent kinases 4/6 inhibitors and it has been approved in 2017 for the treatment of patients with hormone receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. As a drug that has been used for treatment of breast cancer for only few years its rare side effects are described through different case reports. Skin photosensitivity represents a range of dermatological conditions that are caused or exacerbated by sunlight exposure. Drug-induced photosensitivity can be seen in patients treated with all kinds of oncology treatments, including chemotherapeutic agents, targeted anticancer therapies, and immune checkpoint inhibitors. Case outline We present a case of a patient with metastatic hormone receptor positive and HER2- metastatic breast cancer who developed phototoxic skin changes during the treatment with ribociclib/letrozole. During the treatment, the patient developed mild redness of the skin in a strict photosensitive distribution and rash changed to erythematous confluent plaques on the neck and upper part of the chest, face, and forearms. After treatment cessation the skin changes did not reappear. Conclusion As the observed cutaneous adverse effect subsided after the treatment cessation and did not reappear after the initiation of palbociclib/letrozole treatment, it can be concluded that the adverse effects were the consequence of ribociclib action. Management of cutaneous adverse effects is different depending mostly of grade of cutaneous adverse effect and its severity. © 2024, Serbia Medical Society. All rights reserved.